Inovio Pharmaceuticals, Inc.

NasdaqCM:INO Stock Report

Market Cap: US$99.6m

Inovio Pharmaceuticals Management

Management criteria checks 3/4

Inovio Pharmaceuticals' CEO is Jacqueline Shea, appointed in May 2022, has a tenure of 4.17 years. total yearly compensation is $1.59M, comprised of 45.9% salary and 54.1% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $134.33K. The average tenure of the management team and the board of directors is 5.1 years and 7.5 years respectively.

Key information

Jacqueline Shea

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage45.87%
CEO tenure4.2yrs
CEO ownership0.1%
Management average tenure5.1yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Narrative Update • Jun 26

INO: Recent Equity Raises Will Set Up Future Repricing Potential

Analysts have reduced their price target on Inovio Pharmaceuticals stock from $3.00 to $2.50, citing the impact of a higher share count on projected fair value and valuation metrics. What’s in the News for Inovio Pharmaceuticals Inovio Pharmaceuticals completed a follow on equity offering of common stock and Series A and Series B warrants totaling US$17.5 million.
Analysis Article • Jun 26

Here's Why We're A Bit Worried About Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Aug 11

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO Compensation Analysis

How has Jacqueline Shea's remuneration changed compared to Inovio Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$85m

Dec 31 2025US$2mUS$728k

-US$85m

Sep 30 2025n/an/a

-US$108m

Jun 30 2025n/an/a

-US$88m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$2mUS$728k

-US$107m

Sep 30 2024n/an/a

-US$113m

Jun 30 2024n/an/a

-US$122m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$751k

-US$135m

Sep 30 2023n/an/a

-US$165m

Jun 30 2023n/an/a

-US$168m

Mar 31 2023n/an/a

-US$241m

Dec 31 2022US$4mUS$730k

-US$280m

Sep 30 2022n/an/a

-US$332m

Jun 30 2022n/an/a

-US$355m

Mar 31 2022n/an/a

-US$328m

Dec 31 2021US$2mUS$468k

-US$304m

Sep 30 2021n/an/a

-US$221m

Jun 30 2021n/an/a

-US$142m

Mar 31 2021n/an/a

-US$188m

Dec 31 2020US$2mUS$431k

-US$166m

Sep 30 2020n/an/a

-US$180m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$123m

Dec 31 2019US$1mUS$335k

-US$119m

Compensation vs Market: Jacqueline's total compensation ($USD1.59M) is above average for companies of similar size in the US market ($USD658.00K).

Compensation vs Earnings: Jacqueline's compensation has been consistent with company performance over the past year.

CEO

Jacqueline Shea (60 yo)

4.2yrs
Tenure
US$1,587,155
Compensation

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

Leadership Team

NamePositionTenureCompensationOwnership
Jacqueline Shea
CEO, President & Director4.2yrsUS$1.59m0.13%
$ 134.3k
Peter Kies
Chief Financial Officer24.1yrsUS$833.68k0.053%
$ 52.3k
Michael Sumner
Chief Medical Officer & Head of Development4.1yrsUS$910.64k0.051%
$ 50.9k
Laurent Humeau
Chief Scientific Officer & Chairman of the Scientific Advisory Board7.3yrsUS$1.14m0.057%
$ 56.7k
Robert Crotty
General Counsel4.7yrsno datano data
Jennie Willson
Director of Communicationsno datano datano data
E. Brandreth
Senior Vice President of Quality Assuranceno datano datano data
Jeffrey Skolnik
Senior Vice President of Clinical Development5.8yrsno datano data
Robert Juba
Senior Vice President of Biological Manufacturing & Clinical Supply Management5.8yrsno datano data
Shawn Bridy
Senior Vice President of Business Development5.5yrsno datano data
Cheryl Elder
Senior Vice President of Regulatory Affairs3.3yrsno datano data
Steven Egge
Chief Commercial Officer2yrsno datano data
5.1yrs
Average Tenure
60yo
Average Age

Experienced Management: INO's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jacqueline Shea
CEO, President & Director4.2yrsUS$1.59m0.13%
$ 134.3k
Laurent Humeau
Chief Scientific Officer & Chairman of the Scientific Advisory Board2.5yrsUS$1.14m0.057%
$ 56.7k
Wendy Yarno
Independent Director8.6yrsUS$82.50k0.013%
$ 12.7k
Lota Zoth
Independent Director7.5yrsUS$77.50k0.011%
$ 10.6k
Jay Shepard
Independent Director6.5yrsUS$80.00k0.011%
$ 11.1k
Simon Benito
Independent Chairman of Board of Directors22.6yrsUS$117.50k0.015%
$ 14.8k
David B. Weiner
Member of the Scientific Advisory Board & Director10.3yrsUS$52.50k0.11%
$ 106.0k
Stanley Plotkin
Member of Scientific Advisory Board17.1yrsno datano data
Ann Miller
Independent Director7.3yrsUS$91.75k0.012%
$ 12.0k
Roger Dansey
Independent Director5.2yrsUS$72.10k0.011%
$ 10.8k
Rafi Ahmed
Member of Scientific Advisory Board7.7yrsno datano data
7.5yrs
Average Tenure
69yo
Average Age

Experienced Board: INO's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 07:38
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inovio Pharmaceuticals, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Geoffrey MeachamBofA Global Research
Douglas BuchananCitizens JMP Securities, LLC